Table 1.
Demographic, clinical and behavioral characteristics by Chlamydia trachomatis clearance status.
| Characteristic | Total (n = 55) | Cleared Ct (n = 13) | Persisting (n = 42) | p-value a |
|---|---|---|---|---|
| Age, median (range) | 24 (18-35) | 26 (18-30) | 24 (18-35) | 0.32 b |
| Black Race, No (%) | 42 (76.4) | 9 (69.2) | 33 (78.6) | 0.48 |
| ≤ 1 partner in 30 days, No. (%) | 43 (78.2) | 11 (84.6) | 32 (76.2) | 0.71 |
| Hormonal Contraception c , No. (%) | 22 (40.0) | 8 (61.5) | 14 (33.3) | 0.11 |
| Mucopurulent cervicitis, No. (%) | 16 (29.1) | 2 (15.4) | 14 (33.3) | 0.30 |
| Prior Ct, No. (%) | 28 (50.9) | 5 (38.5) | 23 (54.8) | 0.36 |
| Coinfection, No. (%) | ||||
| None d | 23 (41.8) | 7 (53.8) | 16 (38.1) | 0.52 |
| BV Amsel (3-4) | 16 (29.1) | 2 (15.4) | 14 (33.3) | 0.30 |
| BV Nugent (7-10) | 21 (38.2) | 3 (23.1) | 18 (42.3) | 0.33 |
| T. vaginalis | 1 (1.8) | 0 (0.0) | 1 (2.4) | >0.99 |
| Yeast | 4 (7.3) | 2 (15.4) | 2 (4.8) | 0.23 |
| M. genitalium | 7 (12.7) | 0 (0.0) | 7 (16.7) | 0.18 |
| HSV | 2 (3.6) | 1 (7.7) | 1 (2.4) | 0.42 |
| Days to enrollment, median (range) | 9 (4-31) | 9 (7-23) | 9 (4-31) | 0.92 b |
| BV Treated at Screen, No (%) | 28 (50.9) | 7 (53.8) | 21 (50.0) e | >0.99 |
| Metronidazole Rx/Adhered at Screen, No (%) | 26 (47.3) | 7 (53.9) | 19 (45.2) f | 0.76 |
| Treatment success (Amsel 0-2) | 22 (84.6) | 6 (85.7) | 16 (84.2) | >0.99 |
| Treatment success (Nugent<7) | 17 (65.4) | 6 (85.7) | 11 (57.9) | 0.36 |
| Treatment success (by CST) e |
15 (57.7) | 6 (85.7) | 9 (50%) | 0.18 |
a
Fisher’s exact test, unless otherwise indicated.
b
Mann-Whitney test.
c
Hormonal contraception includes Mirena, Depo-Provera, oral contraceptives, and Paragard.
d
Coinfection includes BV-Amsel, BV-Nugent, Trichomonas vaginalis, yeast, Mycoplasma genitalium, HSV.
e
Two patients in persisting group did not adhere to treatment.
f
CST available on 25/26 of those treated for BV symptoms at screen.